<sup>11</sup>C-flumazenil受体显像在缺血半暗带研究中的进展

张军

¹¹C-flumazenil受体显像在缺血半暗带研究中的进展

张军

文章导航 > 国际放射医学核医学杂志 > 2004, 28 > 6: (246-249)

引用本文:

Citation:

¹¹C-flumazenil受体显像在缺血半暗带研究中的进展

张军

430022 武汉, 华中科技大学同济医学院附属协和医院核医学科
中图分类号: R817.4

Advances of ¹¹C-flumazenil receptor imaging in ischemic penumbra

ZHANG Jun

Department of Nuclear Medicine, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
CLC number: R817.4

摘要: 缺血半暗带是缺血性卒中的治疗目标,故而研究出一种早期精确判定脑组织活性的显像方法极为重要。PET神经受体显像,尤其是¹¹C-flumazenil受体显像不仅可早期鉴别神经元的功能性或形态性损伤,将不可逆性损伤组织与半暗带区分开来,还可预测脑梗死的恶性病程,从而有助于介入治疗病例的选择及正确治疗策略的制订。
- 缺血半暗带 /
- 正电子发射体层显像 /
- ¹¹C-flumazenil /
- 受体显像
Abstract: The ischemic penumbra is the target of therapy for ischemic stroke patients, so it is extremely important to investigate an imaging technique that may identify accurately the viability of cerebral tissues early. The neuroreceptor imaging with positron emission tomography has achieved some successes in this study field, in particular, the ¹¹C-flumazenil receptor imaging, which can not only differentiate between the neurons of functional impairment and those of morphological destruction, and then distinguish the is-chemic penumbra from the irreversible damage tissues, but predict the malignant course of cerebral infarction. Consequently, these will help to select the patients benefiting from the intervention therapy and plan effectively the therapeutic strategies.
- ischemic penumbra /
- positron emission tomography /
- ¹¹C-flumazenil /
- receptor imaging
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Heiss WD.Best measure of ischemic penumbra:positron emission tomography[J].Stroke,2003,34(10):2534-2535.
[2]	Heiss WD,Grond M,Thiel A,et al.Tissue at risk of infarction rescued by early reperfusion:a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke[J].J Cereb Blood Flow Metab,1998,18(12):1298-1307.
[3]	Warach S.Measurement of the ischemic penumbra with MRI:it's about time[J].Stroke,2003,34(10):2533-2534.
[4]	Sette G,Baron JC,Young AR,et al.In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon[J].Stroke,1993,24(12):2046-2057.
[5]	Heiss WD,Graf R,Fujita T,et al.Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats[J].Stroke,1997,28(10):2045-2051.
[6]	Heiss WD,Grond M,Thiel A,et al.Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke[J].Stroke,1998,29(2):454-461.
[7]	Heiss WD,Kracht L,Grond M,et al.Early[¹¹C] Flumazenil/H₂O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy[J].Stroke,2000,31(2):366-369.
[8]	Heiss WD,Kracht LW,Thiel A,et al.Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia[J].Brain,2001,124(1):20-29.
[9]	Dohmen C,Bosche B,Graf R,et al.Prediction of malignant course in MCA infarction by PET and microdialysis[J].Stroke,2003,34(9):2152-2158.
[10]	Grunder G,Siessmeier T,Lange-Asschenfeldt C,et al.[¹⁸F]Fluo-roethyl-flumazenil:a novel tracer for PET imaging of human benzodiazepine receptors[J].Eur J Nucl Med,2001,28(10):1463-1470.
[11]	Nakagawara J,Sperling B,Lassen NA.Incomplete brain infarction of reperfused cortex may be quantitated with iomazenil[J].Stroke,1997,28(1):124-132.
[12]	Nariai T,Shimada Y,Ishiwata K,et al.PET imaging of adenosine A₁ receptors with ¹¹C-MPDX as an indicator of severe cerebral ischemic insult[J].J Nucl Med,2003,44(11):1839-1844.
[13]	Ishiwata K,Nariai T,Kimura Y,et al.Preclinical studies on[¹¹C] MPDX for mapping adenosine A1 receptors by positron emission tomography[J].Ann Nucl Med,2002,16(6):377-382.
[14]	Fukumitsu N,Ishii K,Kimura Y,et al.Imaging of adenosine A1 receptors in the human brain by positron emission tomography with[¹¹C] MPDX[J].Ann Nucl Med,2003,17(6):511-515.

[1]	王艺东 . 乏氧显像确认脑缺血半暗带的研究进展. 国际放射医学核医学杂志, 2003, 27(1): 8-10.
[2]	李林 , 谭天秩 . 层粘素受体显像. 国际放射医学核医学杂志, 1999, 23(6): 245-247.
[3]	张春丽 , 王荣福 . 肿瘤受体显像. 国际放射医学核医学杂志, 2000, 24(3): 124-127,141.
[4]	匡安仁 , 谭天秩 . 基本的受体显像数学模型和方法. 国际放射医学核医学杂志, 1997, 21(1): 21-25.
[5]	段炼 , 李险峰 . 甲状腺相关眼病与生长抑素受体显像. 国际放射医学核医学杂志, 2005, 29(3): 108-111.
[6]	李前伟 , 谭天秩 , 林汉 . 放射性核素标记血管活性肠肽的肿瘤受体显像. 国际放射医学核医学杂志, 1996, 20(3): 124-128.
[7]	施可欣 , 张晓辉 , 金晨涛 , 田梅 . PET受体显像在肥胖人群神经功能改变成像中的作用. 国际放射医学核医学杂志, 2019, 43(6): 523-527. doi: 10.3760/cma.j.issn.1673-4114.2019.06.006
[8]	王雪鹃 , 张梅颖 , 林保和 . 肿瘤血管活性肠肽受体显像. 国际放射医学核医学杂志, 2001, 25(2): 65-69.
[9]	邱春 , 管一晖 . 5-羟色胺受体显像剂在神经系统疾病及脑功能研究中的应用. 国际放射医学核医学杂志, 2011, 35(2): 73-80, 127. doi: 10.3760/cma.j.issn.1673-4114.2011.02.003
[10]	袁志斌 . 正电子肿瘤阳性显像剂¹⁸F-AMT. 国际放射医学核医学杂志, 2002, 26(5): 193-195.

点击查看大图

计量

文章访问数: 1110
HTML全文浏览量: 100
PDF下载量: 2

¹¹C-flumazenil受体显像在缺血半暗带研究中的进展

张军

430022 武汉, 华中科技大学同济医学院附属协和医院核医学科

收稿日期: 2004-04-11

关键词:

摘要: 缺血半暗带是缺血性卒中的治疗目标,故而研究出一种早期精确判定脑组织活性的显像方法极为重要。PET神经受体显像,尤其是¹¹C-flumazenil受体显像不仅可早期鉴别神经元的功能性或形态性损伤,将不可逆性损伤组织与半暗带区分开来,还可预测脑梗死的恶性病程,从而有助于介入治疗病例的选择及正确治疗策略的制订。